340 related articles for article (PubMed ID: 30828772)
1. Autologous Haematopoietic Stem Cell Transplantation in Multiple Sclerosis: a Review of Current Literature and Future Directions for Transplant Haematologists and Oncologists.
Das J; Sharrack B; Snowden JA
Curr Hematol Malig Rep; 2019 Apr; 14(2):127-135. PubMed ID: 30828772
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of autologous haematopoietic stem cell transplantation versus alemtuzumab, ocrelizumab, ofatumumab or cladribine in relapsing remitting multiple sclerosis (StarMS): protocol for a randomised controlled trial.
Brittain G; Petrie J; Duffy KEM; Glover R; Hullock K; Papaioannou D; Roldan E; Beecher C; Bursnall M; Ciccarelli O; Coles AJ; Cooper C; Giovannoni G; Gabriel I; Kazmi M; Kyriakou C; Nicholas R; Paling D; Peniket A; Scolding N; Silber E; de Silva T; Venneri A; Walters SJ; Young C; Muraro PA; Sharrack B; Snowden JA;
BMJ Open; 2024 Feb; 14(2):e083582. PubMed ID: 38316583
[TBL] [Abstract][Full Text] [Related]
3. Autologous haematopoietic stem cell therapy for multiple sclerosis: a review for supportive care clinicians on behalf of the Autoimmune Diseases Working Party of the European Society for Blood and Marrow Transplantation.
Ismail A; Sharrack B; Saccardi R; Moore JJ; Snowden JA
Curr Opin Support Palliat Care; 2019 Dec; 13(4):394-401. PubMed ID: 31599815
[TBL] [Abstract][Full Text] [Related]
4. Autologous haematopoietic stem cell transplantation for multiple sclerosis: a position paper and registry outline.
Bayas A; Berthele A; Blank N; Dreger P; Faissner S; Friese MA; Gerdes LA; Grauer OM; Häussler V; Heesen C; Janson D; Korporal-Kuhnke M; Kowarik M; Kröger N; Lünemann JD; Martin R; Meier U; Meuth S; Muraro P; Platten M; Schirmer L; Stürner KH; Stellmann JP; Scheid C; Bergh FT; Warnke C; Wildemann B; Ziemssen T
Ther Adv Neurol Disord; 2023; 16():17562864231180730. PubMed ID: 37780055
[TBL] [Abstract][Full Text] [Related]
5. Healthcare utilization and costs associated with autologous haematopoietic stem cell transplantation in Norwegian patients with relapsing remitting multiple sclerosis.
Gottschlich KN; Zolic-Karlsson Z; Aas E; Kvistad SAS; Bø L; Torkildsen Ø; Lehmann AK
Mult Scler Relat Disord; 2024 Apr; 84():105507. PubMed ID: 38412758
[TBL] [Abstract][Full Text] [Related]
6. Autologous hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: comparison with secondary progressive multiple sclerosis.
Casanova B; Jarque I; Gascón F; Hernández-Boluda JC; Pérez-Miralles F; de la Rubia J; Alcalá C; Sanz J; Mallada J; Cervelló A; Navarré A; Carcelén-Gadea M; Boscá I; Gil-Perotin S; Solano C; Sanz MA; Coret F
Neurol Sci; 2017 Jul; 38(7):1213-1221. PubMed ID: 28396953
[TBL] [Abstract][Full Text] [Related]
7. Long-term outcomes of autologous hematopoietic stem cell transplantation with reduced-intensity conditioning in multiple sclerosis: physician's and patient's perspectives.
Shevchenko JL; Kuznetsov AN; Ionova TI; Melnichenko VY; Fedorenko DA; Kurbatova KA; Gorodokin GI; Novik AA
Ann Hematol; 2015 Jul; 94(7):1149-57. PubMed ID: 25711670
[TBL] [Abstract][Full Text] [Related]
8. Haematopoietic Stem Cell Transplantation for the Treatment of Multiple Sclerosis: Recent Advances.
Mariottini A; De Matteis E; Cencioni MT; Muraro PA
Curr Neurol Neurosci Rep; 2023 Sep; 23(9):507-520. PubMed ID: 37589918
[TBL] [Abstract][Full Text] [Related]
9. Prospective phase II clinical trial of autologous haematopoietic stem cell transplant for treatment refractory multiple sclerosis.
Moore JJ; Massey JC; Ford CD; Khoo ML; Zaunders JJ; Hendrawan K; Barnett Y; Barnett MH; Kyle KA; Zivadinov R; Ma KC; Milliken ST; Sutton IJ; Ma DDF
J Neurol Neurosurg Psychiatry; 2019 May; 90(5):514-521. PubMed ID: 30538138
[TBL] [Abstract][Full Text] [Related]
10. Autologous hematopoietic stem cell transplantation significantly alters circulating ceramides in peripheral blood of relapsing-remitting multiple sclerosis patients.
Vaivade A; Wiberg A; Khoonsari PE; Carlsson H; Herman S; Al-Grety A; Freyhult E; Olsson-Strömberg U; Burman J; Kultima K
Lipids Health Dis; 2023 Jul; 22(1):97. PubMed ID: 37420217
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of autologous hematopoietic stem-cell transplantation in multiple sclerosis: a systematic review and meta-analysis.
Ge F; Lin H; Li Z; Chang T
Neurol Sci; 2019 Mar; 40(3):479-487. PubMed ID: 30535563
[TBL] [Abstract][Full Text] [Related]
12. Intense immunosuppression followed by autologous haematopoietic stem cell transplantation as a therapeutic strategy in aggressive forms of multiple sclerosis.
Mancardi G; Sormani MP; Muraro PA; Boffa G; Saccardi R
Mult Scler; 2018 Mar; 24(3):245-255. PubMed ID: 29125439
[TBL] [Abstract][Full Text] [Related]
13. Autologous Hematopoietic Cell Transplantation for Treatment-Refractory Relapsing Multiple Sclerosis: Position Statement from the American Society for Blood and Marrow Transplantation.
Cohen JA; Baldassari LE; Atkins HL; Bowen JD; Bredeson C; Carpenter PA; Corboy JR; Freedman MS; Griffith LM; Lowsky R; Majhail NS; Muraro PA; Nash RA; Pasquini MC; Sarantopoulos S; Savani BN; Storek J; Sullivan KM; Georges GE
Biol Blood Marrow Transplant; 2019 May; 25(5):845-854. PubMed ID: 30794930
[TBL] [Abstract][Full Text] [Related]
14. Autologous hematopoietic cell transplantation in multiple sclerosis.
Bell SM; Sharrack B; Snowden JA
Expert Opin Biol Ther; 2017 Jan; 17(1):77-86. PubMed ID: 27657737
[TBL] [Abstract][Full Text] [Related]
15. Impact of autologous haematopoietic stem cell transplantation on disability and brain atrophy in secondary progressive multiple sclerosis.
Mariottini A; Filippini S; Innocenti C; Forci B; Mechi C; Barilaro A; Fani A; Carlucci G; Saccardi R; Massacesi L; Repice AM
Mult Scler; 2021 Jan; 27(1):61-70. PubMed ID: 32008439
[TBL] [Abstract][Full Text] [Related]
16. Autologous haematopoietic stem cell transplantation versus low-dose immunosuppression in secondary-progressive multiple sclerosis.
Mariottini A; Bulgarini G; Forci B; Innocenti C; Mealli F; Mattei A; Ceccarelli C; Repice AM; Barilaro A; Mechi C; Saccardi R; Massacesi L
Eur J Neurol; 2022 Jun; 29(6):1708-1718. PubMed ID: 35146841
[TBL] [Abstract][Full Text] [Related]
17. [Multiple sclerosis: interventions to halt disease : Which patients can be considered for autologous stem cell transplantation].
Willison AG; Meuth SG
Nervenarzt; 2022 Oct; 93(10):987-999. PubMed ID: 35951049
[TBL] [Abstract][Full Text] [Related]
18. Effect of autologous hematopoietic stem cell transplantation on multiple sclerosis and neuromyelitis optica spectrum disorder: a PRISMA-compliant meta-analysis.
Zhang P; Liu B
Bone Marrow Transplant; 2020 Oct; 55(10):1928-1934. PubMed ID: 32020080
[TBL] [Abstract][Full Text] [Related]
19. Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial.
Atkins HL; Bowman M; Allan D; Anstee G; Arnold DL; Bar-Or A; Bence-Bruckler I; Birch P; Bredeson C; Chen J; Fergusson D; Halpenny M; Hamelin L; Huebsch L; Hutton B; Laneuville P; Lapierre Y; Lee H; Martin L; McDiarmid S; O'Connor P; Ramsay T; Sabloff M; Walker L; Freedman MS
Lancet; 2016 Aug; 388(10044):576-85. PubMed ID: 27291994
[TBL] [Abstract][Full Text] [Related]
20. Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multi-centre experience.
Mancardi GL; Sormani MP; Di Gioia M; Vuolo L; Gualandi F; Amato MP; Capello E; Currò D; Uccelli A; Bertolotto A; Gasperini C; Lugaresi A; Merelli E; Meucci G; Motti L; Tola MR; Scarpini E; Repice AM; Massacesi L; Saccardi R;
Mult Scler; 2012 Jun; 18(6):835-42. PubMed ID: 22127896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
